Calendario›REGN›ALN-CIDEB

ALN-CIDEB

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Metabolic Dysfunction-Associated Steatotic Liver Disease · Metabolic Dysfunction-Associated Steatohepatitis (del registro, en inglés).

Fase

Fase 1/2

Estado

Reclutando pacientes

Participantes

132

previstos

Centros

4

Fin del objetivo primario

may 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, doble ciego. Comenzó en abr 2025.

Qué mide

Incidence of Treatment-Emergent Adverse Events (TEAEs) (del registro, en inglés) (hasta 48 semanas)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B). MASLD and MASH are long-lasting liver conditions caused by having too much fat in the liver. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How the study drug works to change liver fat content * How much study drug and study drug metabolites (byproducts of the body breaking down the study drug) are in the blood at different times

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06836609), actualizada en jul 2026.